Northland Capmk Lowers Oncternal Therapeutics (NASDAQ:ONCT) to Hold

Oncternal Therapeutics (NASDAQ:ONCT) was downgraded by Northland Capmk from a “strong-buy” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports.

ONCT has been the subject of several other research reports. Northland Securities reaffirmed a “market perform” rating and set a $2.00 price target on shares of Oncternal Therapeutics in a research note on Thursday. Brookline Capital Management restated a “hold” rating on shares of Oncternal Therapeutics in a research report on Thursday. HC Wainwright cut their target price on Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Finally, StockNews.com began coverage on shares of Oncternal Therapeutics in a research note on Sunday, September 8th. They set a “hold” rating on the stock. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Oncternal Therapeutics currently has a consensus rating of “Hold” and an average target price of $20.00.

Oncternal Therapeutics Stock Down 14.1 %

NASDAQ:ONCT opened at $1.46 on Thursday. The stock has a market cap of $4.32 million, a P/E ratio of -0.12 and a beta of 1.39. The business’s 50-day moving average price is $5.37 and its two-hundred day moving average price is $7.48. Oncternal Therapeutics has a twelve month low of $1.32 and a twelve month high of $13.14.

Oncternal Therapeutics (NASDAQ:ONCT) last announced its earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.03) by $0.14. Oncternal Therapeutics had a negative net margin of 1,948.70% and a negative return on equity of 136.10%. The business had revenue of $0.80 million for the quarter, compared to the consensus estimate of $0.24 million. During the same period last year, the firm posted ($3.00) earnings per share. On average, equities research analysts expect that Oncternal Therapeutics will post -11.4 EPS for the current fiscal year.

Institutional Investors Weigh In On Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC acquired a new stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned 0.84% of Oncternal Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.